News | Cardiovascular Business | February 28, 2022

Cardiovascular Disease Concerns Pump Sales of Cardiac Markers to $2.5 Billion

Healthcare publisher, Kalorama Information, shares insights from its latest report on the Cardiac Markers market

image of a heart

February 28, 2022 – Despite improvements in treatment and increased public awareness about prevention, cardiovascular disease (CVD) is still the leading cause of death worldwide. CVD causes half of all deaths in several developed countries and is the major cause of adult death in many developing countries. And though some cardiovascular events aren't fatal, strokes and other forms of heart disease may still be debilitating enough to seriously affect functional ability. These concerns are contributing to growth in sales of cardiac markers, according to World Market for Cardiac Markers (POC and Lab-Based), a recent report by medical market research firm Kalorama Information.

Cardiac markers generated an estimated $2.52 billion in sales during 2021, largely as a result of the prevalence of cardiovascular diseases, including those of the blood vessels supplying the heart muscle and the brain. Looking ahead, the market is forecast to increase by a compound annual growth rate (CAGR) of 4.1% between 2021-2026, reveals World Market for Cardiac Markers (POC and Lab-Based).

“With the incidence of cardiovascular disease going through the roof, cardiac markers are in huge demand and a constant subject of research for improvement,” said Bruce Carlson, publisher for Kalorama Information.

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. In patients with chronic heart failure, measurement of these biomarkers is used to help risk stratify, to assess treatment options, monitor progress, and guide in-hospital and post-discharge care.

Physicians use cardiac markers in two ways—to diagnose a cardiac event in a hospital emergency room (acute care) or to evaluate the risk of a cardiovascular event occurring. The traditional markers—BNP, troponin and myoglobin are used in the acute care and tests such as cholesterol are used to evaluate risk.

An aging population combined with advancements in technology are innovating the market as health care providers seek ways to meet the demand for high levels of service in a more cost-effective manner.

For more information: https://kaloramainformation.com/product/world-market-for-cardiac-markers-poc-and-lab-based/.

Related cardiovascular disease content:

A Decade of Women’s Heart Health, Reexamined

Two Elevated Biomarkers Distinguish Blacks with Resistant Hypertension

Adolescent Psychological Well-being Tied to Adult Risk of Cardiovascular Disease, Study Finds


Related Content

News | Cardiovascular Business

April 9, 2024 — Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as ...

Home April 09, 2024
Home
News | Cardiovascular Business

April 5, 2024 — The Cardiovascular Research Foundation (CRF) has announced New York Valves: The Structural Heart Summit ...

Home April 05, 2024
Home
News | Cardiovascular Business

April 5, 2024 — Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive ...

Home April 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a Top 10 look at the content that was trending during the month of March on dicardiology.com: 1. CLS Health ...

Home April 04, 2024
Home
News | Cardiovascular Business

March 19, 2024 — The American College of Cardiology (ACC) has selected 50 learners for its 2024 – 2025 Clinical Trials ...

Home March 19, 2024
Home
News | Cardiovascular Business

March 19, 2024 — Titan Medical Inc. announced that it has entered into a definitive amalgamation agreement (the ...

Home March 19, 2024
Home
News | Cardiovascular Business

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
News | Cardiovascular Business

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
News | Cardiovascular Business

March 13, 2024 — Two nationally recognized cardiovascular programs, New Jersey-based Atlantic Health System’s Morristown ...

Home March 13, 2024
Home
News | Cardiovascular Business

March 11, 2024 — VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart ...

Home March 11, 2024
Home
Subscribe Now